FDA approves Ilumya for psoriatic arthritis
Published
Sun Pharma's Ilumya, already used for plaque psoriasis, is now approved for adults with active psoriatic arthritis. It's given only by a health care provider, which the company says may suit people who can't or prefer not to inject themselves. The most common side effects in studies were upper respiratory infections and COVID-19.
Source: Sun Pharma via BioSpace
This is a plain-language summary. Read the original source for full details.